Authors
Latest:
Dr. Cobleigh on the Focus of Future Research in HER2+ Breast CancerMelody A. Cobleigh, MD, a professor of medical oncology at Rush University Medical Center, discusses the focus of future research in HER2-positive breast cancer.
Latest:
Positive Results from First Randomized Study Assessing T-VEC/Ipilimumab Combo in Advanced MelanomaThe addition of T-VEC (T-VEC; Imlygic), a herpes simplex virus 1-based oncolytic virus, to CTLA-4 inhibitor ipilimumab (Yervoy) improves the objective response rate in patients with unresected stage IIIb to IV melanoma.
Latest:
Dr. Silverstein on Oncoplasty Versus Mastectomy for Patients With Breast CancerMelvin J. Silverstein, MD, FACS, medical director, Hoag Breast Center, Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery, Hoag Memorial Hospital Presbyterian, compares oncoplastic surgery with mastectomy for patients with breast cancer.
Latest:
Researchers Aim to Improve Blood Cancer Outcomes With Engineered T-Cell TreatmentsResearchers at the Seattle Cancer Care Alliance (SCCA) have optimized special methods for modifying T cells to target specific cancer cells in patients with blood cancers.
Latest:
Meredith Buxton on I-SPY 2 Trial for HER2+ Breast CancerMeredith Buxton, PhD, research director, assistant professor, University of California, San Francisco School of Medicine, discusses the I-SPY 2 trial for patients with HER2-positive breast cancer.
Latest:
Dr. Ross on Biomarker Research Development in Liver MetastasisMerrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses biomarker research development for patients with liver metastasis.
Latest:
Dr. Caligiuri on the Anti-KIR Antibody IPH2101Michael A. Caligiuri, MD, CEO, The James Cancer Hospital Solove Research Institute, director, Comprehensive Cancer Center, Ohio State University, discusses the anti-KIR antibody IPH2101 in myeloma and leukemia.
Latest:
Dr. Carducci on the Ongoing CAPItello-280 Trial in mCRPCMichael A. Carducci, MD, discusses the significance of two ongoing clinical trials in prostate cancer: the phase 3 CAPItello-280 trial (NCT05348577) and phase 3 INDICATE study (EA8191; NCT04423211).
Latest:
Dr. Choti on Pursuing Chemotherapy Following Tumor Resection in Advanced CRCMichael A. Choti, MD, discusses pursuing chemotherapy following tumor resection in advanced colorectal cancer.
Latest:
Understanding the Implications of Mandatory Vendor Imposition in OncologyThe rising costs of healthcare have caused payers to analyze spending and take measures to contain costs.
Latest:
Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Latest:
Dr. Poch on Nivolumab as a Treatment for Patients With Bladder CancerMichael A. Poch, MD, urologist and assistant member at Moffitt Cancer Center, discusses the potential of nivolumab (Opdivo) as a treatment for patients with metastatic bladder cancer.
Latest:
Dr. Postow on FDA Approval of Cemiplimab in Metastatic Cutaneous Squamous Cell CarcinomaMichael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of cemiplimab in patients with advanced or metastatic cutaneous squamous cell carcinoma.
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician FactorsFor a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Dr. Savin on the Challenges of Developing Biosimilar Clinical TrialsMichael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the challenges that come with trying to develop a clinical trial for biosimilars.
Latest:
Dr. Thompson on Challenges Facing the Field of Multiple MyelomaMichael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses challenges facing the field of multiple myeloma.
Latest:
Dr. Thompson on the Future of Treatment in Multiple MyelomaMichael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses the future of treatment in multiple myeloma.
Latest:
Dr. Aberger Discusses a Cost Analysis of Testicular Self-ExaminationsMichael Aberger, MD, resident physician, University of Kansas Medical Center, discusses a cost analysis of testicular self-examinations.
Latest:
Dr Andreeff on the Rationale for Investigating Uproleselan Plus Venetoclax and Azacitidine in AMLMichael Andreeff, MD, PhD, discusses the rationale for investigating uproleselan plus venetoclax and azacitidine in patients with acute myeloid leukemia.
Latest:
Rapid Readouts: Results of Phase 3 DREAMseq Trial in Advanced MelanomaMichael Atkins, MD, shares data presented at the 2021 American Society of Clinical Oncology Plenary Series regarding results from the phase 3 ECOG-ACRIN EA6134 trial, DREAMseq, evaluating the use of up-front dual immunotherapy in patients with BRAF V600–mutant advanced melanoma.
